-
2023-504180-16-00
5
2025-04-07
Advanced Breast Cancer
-
2023-505311-20-01
5
2025-03-21
Metastatic Non-Small Cell Lung Cancer
-
2023-510292-65-00
5
2025-02-25
chronic graft-versus-host disease
-
2023-509853-29-00
10
2025-02-24
amyotrophic lateral sclerosis
-
2023-505077-32-00
5
2025-01-28
Locally-advanced or metastatic non-squamous non-small cell lung cancer
-
2024-516510-38-00
4
2025-01-27
Traumatic Brain Injury
-
2023-506675-96-00
5
2025-01-23
Heart Failure
-
2024-511377-30-00
10
2025-01-23
SYMPTOMATIC OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY
-
2023-503675-24-00
5
2025-01-17
Triple-negative Breast Cancer
-
2024-511596-15-00
4
2024-12-26
Liver Diseases, Alcoholic
-
2022-501547-33-01
11
2024-12-24
Acute myocarditis
-
2024-514584-25-00
4
2024-12-16
Small Cell Lung Cancer
-
2023-510380-34-00
4
2024-12-10
Diffuse cutaneous systemic sclerosis (dcSSc)
-
2023-508960-31-00
5
2024-12-03
Metastatic HER2-positive breast cancer
-
2024-517863-22-00
5
2024-12-01
Study population consists in patients with a diagnosis of mCRC who hav
-
2024-512279-10-00
5
2024-11-25
Triple Negative Breast Cancer
-
2024-514917-36-00
5
2024-11-21
Patients with High Risk Neuroblastoma
-
2023-509912-27-00
5
2024-11-07
Metabolic Dysfunction-Associated Steatotic Liver Disease(MASH) / Nonal
-
2023-510395-31-00
5
2024-10-30
Metabolic Dysfunction-Associated Steatohepatitis (MASH) with Compensat
-
2023-509560-16-00
5
2024-10-29
Juvenile psoriatic arthritis (jPsA)
-
2023-509706-30-00
5
2024-10-18
Heart failure (HF)
-
2023-508581-15-00
5
2024-10-08
Heart condition
-
2023-508012-35-00
5
2024-10-02
Newly diagnosed NSCLC with resectable clinical Stage II, IIIA or IIIB
-
2024-515244-22-00
9
2024-09-09
Patients who need to undergo a clinically indicated pharmacologic stre